Haleon plc (NYSE:HLN) Stake Increased by Kathmere Capital Management LLC

Kathmere Capital Management LLC raised its stake in shares of Haleon plc (NYSE:HLN) by 131.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,099 shares of the company’s stock after acquiring an additional 26,744 shares during the quarter. Kathmere Capital Management LLC’s holdings in Haleon were worth $449,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in Haleon by 20.0% during the second quarter. Rhumbline Advisers now owns 48,966 shares of the company’s stock valued at $404,000 after buying an additional 8,160 shares in the last quarter. BOKF NA lifted its stake in Haleon by 68.8% during the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the last quarter. Thoroughbred Financial Services LLC bought a new position in Haleon during the second quarter worth $108,000. Envestnet Asset Management Inc. increased its stake in Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company’s stock valued at $62,549,000 after purchasing an additional 196,843 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Haleon by 21.4% during the second quarter. Brown Brothers Harriman & Co. now owns 7,569 shares of the company’s stock worth $63,000 after purchasing an additional 1,334 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Stock Up 1.2 %

HLN stock opened at $9.12 on Thursday. The firm’s 50-day moving average is $9.56 and its two-hundred day moving average is $9.69. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $41.28 billion, a price-to-earnings ratio of 26.82, a price-to-earnings-growth ratio of 2.95 and a beta of 0.29. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.